Royalty Pharma plc (RPRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total income and other revenues | 578,665 | 568,247 | 564,690 | 537,267 |
| Research and development funding expense | 300,500 | 50,500 | 500 | 500 |
| Provision for changes in expected cash flows from financial royalty assets | -203,938 | -127,140 | -227,604 | 212,429 |
| General and administrative expenses | 179,769 | 110,705 | 56,720 | 54,708 |
| Provision for credit losses on unfunded commitments | 92,535 | - | - | - |
| Total operating expense, net | 368,866 | 34,065 | -170,384 | 267,637 |
| Operating income | 209,799 | 534,182 | 735,074 | 269,630 |
| Other non-operating expenses/(income), net | -1,543 | -3,062 | -1,654 | 6,000 |
| Interest income | 8,327 | 11,290 | 17,508 | 13,381 |
| Interest expense | 68,668 | 65,261 | 66,506 | 49,013 |
| Equity in (earnings)/losses of equity method investees | 2,693 | 6,443 | 10,407 | 1,703 |
| Losses on derivative financial instruments | -2,000 | -1,000 | 3,000 | - |
| Losses/(gains) on equity securities | -30,553 | -45,878 | 50,849 | -47,124 |
| Losses/(gains) on available for sale debt securities | -27,420 | -3,281 | 57,680 | -200 |
| Total other expense, net | -119,164 | -100,749 | 71,284 | -75,253 |
| Consolidated net income before tax | 90,635 | 433,433 | 806,358 | 194,377 |
| Income tax expense | - | - | - | - |
| Consolidated net income | 90,635 | 433,433 | 806,358 | 194,377 |
| Net income attributable to non-controlling interests | 60,459 | 195,084 | 262,371 | 92,373 |
| Net income attributable to royalty pharma plc | 30,176 | 238,349 | 543,987 | 102,004 |
| Basic (in dollars per share) | 0.07 | 0.55 | 1.22 | 0.23 |
| Basic (in shares) | 423,514,000 | 435,480,000 | 447,628,000 | 451,020,000 |
| Diluted (in dollars per share) | 0.07 | 0.55 | 1.21 | 0.23 |
| Diluted (in shares) | 562,298,000 | 578,102,000 | 592,726,000 | 596,912,000 |